|
|
Structural Bases of Ionotropic GABA Receptor Function and
Modulation*
Yongchang Chang, MD, PhD
Division of Neurobiology, Barrow Neurological
Institute, St. Joseph's Hospital and Medical Center, Phoenix,
Arizona
*Courtesy of Yongchang Chang, MD, PhD
The Chang Laboratory
Yongchang Chang received his MD in 1982 at
Sun Yat-Sen University of Medical Sciences, Guangzhou, China and
his PhD in 1998 at the University of Alabama at Birmingham. His
early research experiences include studies of the role of
endogenous opioid peptides in the pathogenesis of hemorrhagic shock
and spectral analysis of the electroencephalogram. His current
research interest is the structure-function relationship of
GABA-gated ion channels.Yun Chen received her MD degree in 2002 at
Zhengzhou University, and master's degree in medical genetics in
2005 at Sun Yat-Sen University. She joined the laboratory in August
2005.
Neurotransmitter-operated (ligand-gated) ion
channels play essential roles in communication between neurons. One
major family of these ligand-gated ion channels includes nicotinic
receptors, serotonin receptor type 3, GABA[A/C] receptors, and the
glycine receptor. The research in our laboratory focuses primarily
on the GABA receptors, the receptors for the major inhibitory
neurotransmitter gamma-aminobutyric acid (GABA) in the brain. These
receptors are the key targets of many clinically useful drugs for
treatment of insomnia, anxiety, and epilepsy and for general
anesthesia. The long-term goal of our laboratory is to provide
structural bases for GABA receptor function and modulation and
mechanisms of action for those drugs acting on GABA receptors by
using an interdisciplinary approach.
Key
Words: activation, allosteric modulation, barbiturates,
benzodiazepines, desensitization, GABA receptor, luminescence
resonance energy transfer, neurosteroids, photocrosslinking,
site-specific flourescence, structure-function relationship
Abbreviations
used: GABA, gamma aminobutyric acid; LRET, luminescence
resonance energy transfer
The brain differs from other organs by its
ability to process information via its interconnected neural
network. The basic building blocks of the neural network,
individual nerve cells called neurons, are excitable cells in the
brain. Their excitability is controlled by a class of membrane
proteins termed ion channels, which selectively allow charged
particles (ions) to pass through the membrane and, in turn, control
the membrane potential of neurons. Neurons can generate and
propagate nerve pulses (action potentials) through voltage-gated
(membrane potential-controlled) ion channels.
Communication between neurons, however, is
mainly achieved by chemical signaling via neurotransmitters and
their receptors (ligand-gated ion channels) at specialized sites
termed synapses, where neurons form functional contacts with each
other. To achieve full control, a neuron receives both excitatory
and inhibitory synaptic inputs. Summation of these opposing
synaptic inputs determines whether a neuron generates an action
potential.
GABA is the major inhibitory neurotransmitter
in the mammalian brain. As a neurotransmitter, GABA is released
into a synaptic cleft by its presynaptic nerve terminus when a
GABA-ergic (GABA releasing) neuron fires an action potential.
Binding GABA to its receptors in the postsynaptic membrane mediates
fast (through ionotropic receptors) and slow (through metabotropic
receptors) synaptic inhibition on the postsynaptic neuron.
Based on their pharmacological properties,
GABA receptors are classified into three types (A, B, and C). The
GABA[B] receptor is a G-protein-linked receptor (metabotropic GABA
receptor) and is not the interest of our study. The GABA[A] and
GABA[C] receptors are GABA-gated chloride channels (ionotropic GABA
receptors). On activation, the channel opens and allows an
influx of negatively charged chloride ions through the pore.
In turn, the postsynaptic membrane becomes hyperpolarized
(resulting in a more negative intracellular potential) and produces
an inhibitory effect on the postsynaptic neuron. Through this
action, ionotropic GABA receptors play an important role in
controlling neuronal excitability. The long-term goal of this
laboratory is to provide structural bases for the mechanisms of the
ionotropic GABA receptor function and mechanisms of action for
drugs that act on ionotropic GABA receptors.
Figure 1. (A) Proposed subunit topology and (B) pentameric
structure of a GABA-gated
ion channel. Figure 1B adapted from Nayeem N, Green TP, Martin IL,
Barnard EA: Quater-
nary structure of the native GABA[A] receptor determined by
electron microscopic image
analysis. J Neurochem 62(2):815-818, 1994, with permission from
Blackwell Publishing.
|
Structure and Function of Ionotropic GABA Receptors
Molecular cloning studies have revealed several different classes
of the ionotropic GABA receptor subunits and their isoforms alpha
1-6, beta 1-3, gamma 1-3, delta, epsilon, rho 1-3, theta, pi, and
chi. They are homologous with 70 to 80% amino acid identity
among isoforms of each class and 30 to 40% sequence identity
between classes.8 They all belong to a ligand-gated ion
channel gene family, which includes nicotinic receptors, serotonin
(5-HT3) receptor type 3, glycine receptors, and GABA[A] and GABA[C]
receptors.[13,15]
The proposed topology for each subunit is a
large extracellular N-terminal domain, four transmembrane domains
(M1-M4), and a large intracellular loop between M3 and M4 (Fig.
1A). The extracellular N-terminal domain forms the agonist-binding
pocket, presumably at the subunit-subunit interface. The
ion-conducting pore is formed by transmembrane domains (M1-M4). The
large intracellular loop can interact with intracellular proteins
for receptor targeting or clustering.
Like other members of this receptor family, a
functional GABA receptor has five subunits. The pentameric
structure of the affinity purified native GABA[A] receptor was
first directly demonstrated by electron microscopy (Fig.
1B).[11] A GABA receptor can be formed by five identical
(homomeric) or different (heteromeric) subunits. Different
subunits, isoforms, or their combinations can form functional
channels with distinct properties, generating the functional
diversity of GABA-gated ion channels. Theoretically, thousands of
combinations of subunits and their isoforms are possible in a
pentameric receptor. In reality, however, only a limited
number of combinations exist. A typical GABA[A] receptor is
composed of alpha, beta, and gamma subunits with a stoichiometry of
two alpha, two beta‚ and one gamma subunits.[3]
The most abundant GABA[A] receptor subtype in
the mammalian brain is alpha 1 beta 2 gamma 2.9 When
exogenously expressed, the recombinant alpha 1 beta 2 gamma 2 GABA
receptor has pharmacological and physiological properties similar
to the typical native GABA[A] receptors, whereas the rho 1 subunit
can form a homomeric GABA receptor with properties similar to
native GABA[C] receptors.
Structural Model of
the N-Terminal Domain: GABA and Benzodiazepine Binding
Sites
A typical GABA[A] receptor has two agonist
binding pockets located in two subunit interfaces between beta and
alpha subunits. The rho 1 homomeric GABA[C] receptor has five
potential binding pockets in the subunit interfaces. The crystal
structure of a homologous protein, acetylcholine binding protein,
was used to generate homologous structural models of GABA[A] and
GABA[C] receptor N-terminal domains (Fig. 2). The binding residues
face subunit interfaces and form the putative binding pockets in
the subunit interfaces. GABA[A] receptor activation also can be
modulated by benzodiazepines. The benzodiazepine binding site is
homologous to the agonist binding site, but it is located in a
different subunit interface (between alpha 1 and gamma 2 subunits)
in the N-terminal domain.
Figure 2. Location of the agonist and benzodiazepine (BZ) binding
pockets (highlighted with side-chain) in the subunit interface of
the (A) GABA[A] and (B) GABA[B] receptors.
|
Structural Model
of Transmembrane Domains: Gating Machinery and Modulatory
Sites
The ion channel part of ionotropic GABA
receptors is formed by transmembrane domains. A structural
model of GABA[A] receptor transmembrane domains was generated by
homology modeling using the structure of the Torpedo nicotinic
receptor based on electron microscopy (Fig. 3). Five subunits, each
with four transmembrane domains (M1-M4), form a pseudosymmetric
pentameric structure with the ion channel pore in the center. The
second transmembrane domain (M2) lines the pore (Fig. 3A with M2 in
the closed-channel position). The M2 domains are slightly kinked in
the middle and form the ion channel gate to control opening and
closing of the channel (Fig. 3B).
Accumulating evidence suggests that the transmembrane domains are
also the major target for many clinically useful GABA[A] receptor
modulators, such as neurosteroids, barbiturates, and general
anesthetics (e.g., propofol).[12] Most of these compounds can
potentiate the effect of GABA at low concentrations and directly
activate the channel at high concentrations. Binding sites for
these compounds are mainly located in the extracellular ends of M1,
M2, and M3 (Fig. 3B). However, the detailed mechanisms of
their action are still unknown.
Figure 3. Homology model of transmembrane domain of a GABA[A]
receptor. The ion channel (center pore) is formed by five subunits,
each with four transmembrane domains (M1-M4). (A) M2 lines the pore
(top view). (B) Side view of transmembrane domains of one subunit
with putative gate and binding sites (circle) for many GABA[A]
receptor modulators.
|
Figure 4. Coupling of agonist binding to channel
opening in the GABA[A] receptor is mediated by
charge interaction between the N-terminal do-
main and M2-M3 linker (highlighted by circle).
|
GABA Receptor
Activation: Coupling of Binding Domain to Channel Gate
Neurotransmitter-operated ion channels open
in response to agonist binding. The conformational wave of the ion
channel is initiated by the interaction of the agonist with its
binding site. It must then propagate to the other parts of
N-terminal domains and eventually to the gating machinery to open
the channel.
A recent study with electron microscopy with
a resolution of 4 Å has revealed more details of the
activation mechanism of the Torpedo nicotinic receptor.10 In
this model, the agonist binding to its binding pocket induces the
N-terminal domain of each subunit to rotate. Subsequently, this
rotation propagates to the gating machinery (M2) to open the pore
through direct coupling between a short loop in the lower part of
the N-terminal inner sheet and the end of M2.
In the heteromeric GABA[A] receptor, two
agonist binding sites are available. Therefore, the receptor
activation involves two binding steps,1 with the receptor at low
affinity in the resting state(s) and at high affinity in the open
state(s).[4] Although the detailed structural mechanism is
unknown, channel opening involves conformational changes in both
the gating machinery (opening) and the agonist binding pocket
(increase in affinity). A recent study using site-directed
mutagenesis and cross-linking suggested that the coupling mechanism
for the channel activation is mediated by charge interactions
between the N-terminal domain and M2-M3 linker (Fig. 4).[7]
Activation of the homomeric rho 1 GABA[C] receptor requires three
bindings to the five potential binding sites. Because gating
can influence binding, channel opening of the homomeric rho 1
GABA[C] receptor can increase binding affinity to GABA to such an
extent that the agonist appears to be locked in the binding site
distant from the pore.[5] This increase in affinity during
channel opening is similar to that in GABA[A] receptors. However,
the detailed dynamic structural basis for this mutual influence of
binding and gating during activation of GABA receptors is not yet
established.
GABA
Receptor Desensitization: Uncoupling?
Binding of an agonist to the GABA[A], but not
GABA[C], receptor can also simultaneously drive the receptor into a
refractory state termed desensitization (decreased
sensitivity). This state may play an important role in
shaping synaptic inhibition. Desensitization of a
ligand-gated ion channel involves conversion of the receptor from a
low-affinity resting state to a high-affinity desensitized state2
and a change in the pore region to close the channel.
Although the kinetic mechanism of desensitization for the GABA[A]
receptor is well characterized,2 the structural basis of these
changes remains poorly understood.
GABA[A] Receptor
Allosteric Modulation: Drug Action
GABA[A] receptors can be potentiated by
modulators, such as benzodiaz- epines, barbiturates, and
neurosteroids. By binding to a site in the receptor distant from
the GABA binding site, these modulators allosterically (distantly)
modulate GABA[A] receptor function. Benzodiazepines are the best
example of GABA[A] receptor modulators. Since their
introduction into medicine in the 1960s, benzodiazepines are also
among the most widely prescribed drugs in the world.
Photoaffinity labeling and site-directed mutagenesis have
identified residues for benzodiazepine binding in alpha (alpha
1H101, Y159, G200, T206, and Y209) and gamma (gamma 2 F77 and M130)
subunits (Fig. 2A). Therefore, the benzodiazepine binding
pocket is homologous to the GABA binding pocket but located in a
different alpha-gamma subunit interface.[14] By binding to a
site distinct from the GABA binding site, these compounds can
change the apparent affinity of the GABA receptor for its agonist.
However, the mechanism underlying this effect is poorly
understood.
Since the early 1900s, barbiturates have been
used as sedative-hypnotics, anticonvulsants, and anesthetics.
They potentiate the GABA response of GABA[A] receptors at low
concentrations and directly activate GABA[A] receptors at high
concentrations. The site of action for barbiturates is not
well defined, but it is distinct from the GABA binding site and
involves the M1, M2 and M3 transmembrane domains. Recent studies
with the substituted cysteine accessibility method have revealed
that direct activation of the GABA[A] receptor by pentobarbital can
cause the agonist binding pocket to narrow. Like
barbiturates, neurosteroid anesthetics can potentiate the GABA
effect at low concentrations and directly gate the GABA[A] receptor
at high concentrations. The binding site for neurosteroids
involves M2 and M4 transmembrane domains. However, experimental
evidence suggests that they are distinct from barbiturate binding
sites.
In summary, benzodiazepines, barbiturates,
and neurosteroids have distinct binding sites, but they have
similar (although not identical) potentiation effects on GABA[A]
receptors. The structural basis for how these compounds have
similar potentiation effects, by binding to distinct sites in a
GABA[A] receptor, awaits future study.
Future Research
The current research interest of the laboratory is focused on the
structural dynamics underlying GABA receptor function and
modulation. Despite intensive structure-function relationship
studies in the past, the dynamic structural basis underlying GABA
receptor function and modulation is still poorly understood. To
this end, the laboratory has successfully adapted several
relatively new techniques to study the structural dynamics of the
GABA receptor: site-specific fluorescence,[6] LRET, and photo
crosslinking. The site-specific fluorescent technique allows
the GABA-induced conformational change to be monitored at a
specific site of the GABA receptor. The LRET technique makes
it possible to measure distance changes, on an atomic scale,
between two residues at different sites of the receptor during
channel activation. The photo cross-linking technique
immobilizes a specific moving part of the receptor, permitting the
functional significance of the movement of a specific amino acid
residue in the receptor to be evaluated. Using these newly
established site-specific fluorescent, luminescent, and
photochemical techniques, combined with electrophysiological,
molecular biological, and computational modeling approaches, the
laboratory has three immediate plans.
First, we will map the structural changes
underlying the activation of the GABA[A/C] receptors.
Although it is known that GABA binding induces conformational
changes to open the channel, the detailed mechanism of this
activation process is still unclear. We hypothesize that activation
of the GABA receptor involves rotation of the receptor subunits, a
mechanism similar to that proposed for the activation of a
nicotinic receptor in the same gene family. Using our newly
adapted techniques, we will systematically map the conformational
changes in GABA[A/C] receptors during channel activation to gain
insights into the detailed dynamic structural mechanism of GABA
receptor activation.
Second, we hope to gain insights into the
structural mechanism of GABA[A] receptor desensitization.
Kinetically, the desensitization of GABA receptors is well
characterized. Structurally, however, the process is poorly
understood. We hypothesize that desensitization involves
over-rotation of the N-terminal domain, which results in uncoupling
of the N-terminus and gating machinery. The over-rotation also
could change interacting residues in the N-terminal interface and
stabilize the receptor in the high-affinity desensitized
state. The newly adapted techniques will be used to
systematically map the conformational rearrangements in GABA[A]
receptors and to correlate these structural changes to functional
desensitization to provide the dynamic structural basis of
GABA-receptor desensitization.
Finally, we plan to define the structural
basis underlying the modulation of GABA[A] receptors by
benzodiazepines, barbiturates, and neurosteroids. As
mentioned, these compounds bind to distinct sites of the GABA[A]
receptor and potentiate the effect of GABA. By systematically
mapping the conformational changes induced by these three different
classes of compounds, we will be able to delineate the patterns of
conformational changes underlying their allosteric
modulation. This information will provide the dynamic
structural basis of how the binding of these compounds to distinct
sites can lead to similar potentiation actions. Systematic mapping
of conformational changes should also suggest insights into the
dynamic structural basis for alternative ways of channel activation
by barbiturates and neurosteroids.
Significance
The ionotropic GABA receptors are widely distributed in the central
nervous system and play a key role in brain function. Dysfunction
of GABA receptors is implicated in the origin of a variety of
neurological and psychiatric disorders such as epilepsy, anxiety,
insomnia, and schizophrenia. GABA receptors are also the key
targets for many widely prescribed neuroactive compounds, such as
benzodiazepines, barbiturates, neurosteroids, and other general
anesthetics. Therefore, it is paramount to elucidate the
mechanism(s) underlying GABA receptor function and modulation.
Although in the past two decades intensive
research has shaped a structural model of the ionotropic GABA
receptors, the structural dynamics underlying their function and
modulation are still not well established. Our work is
intended to unveil novel dynamic structural mechanisms underlying
activation, desensitization, and allosteric modulation of the GABA
receptor. Gaining new insights into the structural dynamics
underlying GABA receptor function and modulation is fundamental for
understanding the pathogenesis of GABA receptor-related
neurological and psychiatric disorders and the mechanism of action
for those compounds with GABA receptors as their major targets.
Such insights also facilitate the development of new drugs that can
improve manipulation of GABA receptor function. In turn, new
treatments may be generated for many neurological and psychiatric
disorders, thereby improving quality of life. This research also
will pave the way for future fluorescence-based studies, such as
studying structural dynamics at the level of single molecules.
References
1. Amin J, Weiss DS: GABA[A] receptor needs two homologous
domains of the beta-subunit for activation by GABA but not by
pentobarbital. Nature 366:565-569,
1993
2. Chang Y, Ghansah E, Chen Y, et al: Desensitization
mechanism of GABA receptors revealed by single oocyte binding and
receptor function. J Neurosci 22:7982-7990,
2002
3. Chang Y, Wang R, Barot S, et al: Stoichiometry of a
recombinant GABA[A] receptor. J Neurosci 16:5415-5424,
1996
4. Chang Y, Weiss DS: Allosteric activation mechanism of the
alpha1beta2gamma2 gamma-aminobutyric acid type A receptor revealed
by mutation of the conserved M2 leucine. Biophys J
77:2542-2551, 1999
5. Chang Y, Weiss DS: Channel opening locks agonist onto the
GABA receptor. Nat Neurosci 2:219-225,
1999
6. Chang Y, Weiss DS: Site-specific fluorescence reveals
distinct structural changes with GABA receptor activation and
antagonism. Nat Neurosci 5:1163-1168,
2002
7. Kash TL, Jenkins A, Kelley JC, et al: Coupling of agonist
binding to channel gating in the GABA[A] receptor. Nature
421:272-275, 2003
8. Macdonald RL, Olsen RW: GABA[A] receptor channels.
Annu Rev Neurosci 17:569-602, 1994
9. McKernan RM, Whiting PJ: Which GABA[A] receptor subtypes
really occur in the brain? Trends Neurosci 19:139-143,
1996
10. Miyazawa A, Fujiyoshi Y, Unwin N: Structure and gating
mechanism of the acetylcholine receptor pore. Nature
423:949-955, 2003
11. Nayeem N, Green TP, Martin IL, et al: Quaternary
structure of the native GABA[A] receptor determined by electron
microscopic image analysis. J Neurochem 62:815-818,
1994
12. Olsen RW, Chang CS, Li G, et al: Fishing for allosteric
sites on GABA(A) receptors. Biochem Pharmacol 68:1675-1684,
2004
13. Ortells MO, Lunt GG: Evolutionary history of the
ligand-gated ion-channel superfamily of receptors. Trends
Neurosci 18:121-127, 1995
14. Sawyer GW, Chiara DC, Olsen RW, et al: Identification of
the bovine gamma-aminobutyric acid type A receptor alpha subunit
residues photolabeled by the imidazobenzodiazepine
[3H]Ro15-4513. J Biol Chem 277:50036-50045,
2002
15. Unwin N: Nicotinic acetylcholine receptor at 9 Å
resolution. J Mol Biol 229:1101-1124, 1993
|